Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,563.08
-1.3931-0.09%
Number of Gainers:3
Number of Losers:4
Number of Flat:- -
PE:- -
High:1,578.56
Open:1,566.93
Low:1,555.65
Close:1,564.47
Volume:49.61M
Turnover:3.97B
Market Cap:1.63T
Float Cap:1.56T

Loading ...

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Political and General News Events from September 8

Reuters
·
Sep 08

Structure Therapeutics Releases Amylin and GLP-1 Program Presentation

Reuters
·
Sep 08

Structure Therapeutics Reports Phase 1/2a Data Showing 3.3% Weight Loss for Oral Amylin Agonist ACCG-2671

Reuters
·
Sep 08

Structure Therapeutics - Aleniglipron Demonstrates up to 16.2% Body Weight Reduction at 72 Weeks in Access Ole Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Accg-2671 Demonstrates About 6-Day Half-Life, no Serious Adverse Events, 3.3% Body Weight Loss in Phase 1/2a Sad Trial

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - Additional Clinical Data for Aleniglipron Expected in Q4 2026

THOMSON REUTERS
·
Sep 08

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and Glp-1 Programs for Chronic Weight Management

THOMSON REUTERS
·
Sep 08

Structure Therapeutics - First Participants Dosed with Accg-2671 in 12-Week Mad Phase 1/2a Trial; Topline Data Expected 1H 2027

THOMSON REUTERS
·
Sep 08

【US Pre-Market】Middle East Energy Risks Escalate, Brent Crude Nears $100, Oil and Gas Stocks Rise; Novartis Plunges 13%

TradingKey
·
Sep 08

Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 08